Mylan Nv Ord Shs (MYL) 46.74 $MYL
Mylan Launches Generic Dexedrine® Capsules
PR Newswire - Mon Aug 01, 6:30AM CDT
Mylan N.V. (NASDAQ, TASE: MYL) today announced the U.S. launch of Dextroamphetamine Sulfate Extended-release Capsules, 5 mg, 10 mg, and 15 mg, a generic version of Amedra Pharmaceuticals LLC's Dexedrine®. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated in narcolepsy and attention deficit disorder with hyperactivity as an integral part of a total treatment program that typically includes other measures (psychological, educational, social) for patients (ages 6 years to 16 years) with this syndrome.(1)
MYL: 46.74 (-0.05)
Mylan Launches Generic Propecia® Tablets
PR Newswire - Mon Aug 01, 6:00AM CDT
Mylan N.V. (NASDAQ, TASE: MYL) today announced the U.S. launch of Finasteride Tablets USP, 1 mg, a generic version of Merck's Propecia®. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated for the treatment of male pattern hair loss (androgenetic alopecia) in men only.
MRK: 58.66 (unch), MYL: 46.74 (-0.05)
Mylan Falls 1.36% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Thu Jul 28, 1:42PM CDT
Mylan (NASDAQ:MYL) traded in a range yesterday that spanned from a low of $45.82 to a high of $46.92. Yesterday, the shares fell 1.4%, which took the trading range below the 3-day low of $46.38 on volume of 1.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
MYL: 46.74 (-0.05)
Look for Shares of Mylan to Potentially Rebound after Yesterday's 1.36% Sell Off
Comtex SmarTrend(R) - Thu Jul 28, 1:41PM CDT
Mylan (NASDAQ:MYL) traded in a range yesterday that spanned from a low of $45.82 to a high of $46.92. Yesterday, the shares fell 1.4%, which took the trading range below the 3-day low of $46.38 on volume of 1.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
MYL: 46.74 (-0.05)
Zacks.com featured highlights: Korea Electric Power, Third Point Reinsurance, Mylan N.V. and Gray Television
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 8:30AM CDT
Zacks.com featured highlights: Korea Electric Power, Third Point Reinsurance, Mylan N.V. and Gray Television
KEP: 27.37 (+0.18), MYL: 46.74 (-0.05), TPRE: 12.60 (+0.01), GTN: 9.78 (-0.12)
Mylan Receives U.S. FTC Clearance for Proposed Meda Acquisition
PR Newswire Europe - Wed Jul 27, 4:19PM CDT
Mylan Has Now Received All Antitrust Regulatory Clearances to Acquire Meda
MYL: 46.74 (-0.05)
4 Buy-Rated Stocks with High Earnings Yield
Zacks Equity Research - Zacks Investment Research - Wed Jul 27, 8:21AM CDT
Earnings yield is a useful ratio for investors who have exposure to both stocks and bonds.
KEP: 27.37 (+0.18), TPRE: 12.60 (+0.01), MYL: 46.74 (-0.05), GTN: 9.78 (-0.12)
The Zacks Analyst Blog Highlights: Manulife Financial, Mylan, Huntsman, Air Lease and Bofi Holding
Zacks Equity Research - Zacks Investment Research - Mon Jul 18, 8:30AM CDT
The Zacks Analyst Blog Highlights: Manulife Financial, Mylan, Huntsman, Air Lease and Bofi Holding
BOFI: 16.09 (-0.73), MFC: 13.42 (-0.21), AL: 28.58 (-0.23), MYL: 46.74 (-0.05), HUN: 15.41 (-0.05)
6 Stocks Still Trading Cheap in Today's Market
Zacks Equity Research - Zacks Investment Research - Fri Jul 15, 2:58PM CDT
We believe it's time to let go of popular stocks and instead focus on the ones trading below fair value.
BOFI: 16.09 (-0.73), MFC: 13.42 (-0.21), AL: 28.58 (-0.23), MYL: 46.74 (-0.05), HUN: 15.41 (-0.05), IX: 69.93 (-0.24)
Market Updates on Drugs - Generic Equities -- Mylan, Horizon Pharma, Allergan, and Diplomat Pharmacy
PR Newswire - Fri Jul 15, 6:30AM CDT
On Thursday, July 14, 2016, the NASDAQ Composite ended the trading session at 5,034.06, up 0.57%; the Dow Jones Industrial Average edged 0.73% higher, to finish at 18,506.41; and the S&P 500 closed at 2,163.75, up 0.53%. The gains were broad based as eight out of nine sectors ended the session in positive. Stock-Callers.com has initiated coverage on the following equities: Mylan N.V. (NASDAQ: MYL), Horizon Pharma PLC (NASDAQ: HZNP), Allergan PLC (NYSE: AGN), and Diplomat Pharmacy Inc. (NYSE: DPLO). Learn more about these stocks by accessing their free notes at:
AGN: 254.86 (+1.91), DPLO: 35.72 (-0.21), HZNP: 18.89 (-0.40), MYL: 46.74 (-0.05)
Teva (TEVA) Provides 2016-2019 Outlook, Shares Gain
Arpita Dutt - Zacks Investment Research - Thu Jul 14, 7:10AM CDT
Teva (TEVA) provided its preliminary outlook for 2016-2019 and expects the Actavis Generics acquisition to go through anytime soon.
AGN: 254.86 (+1.91), MYL: 46.74 (-0.05), TEVA: 53.61 (+0.11), RDY: 44.50 (+0.85)
Looking For Generic Drug Stocks? Pick Up These Winners
Zacks Premium Research - Zacks Investment Research - Wed Jul 13, 5:27PM CDT
The short term earnings outlook for these stocks have been building momentum recently, so don't miss out!
MYL: 46.74 (-0.05), RDY: 44.50 (+0.85), AMPH: 16.29 (+0.11)
SmarTrend Watching for Potential Pullback in Shares of Mylan After 1.51% Gain
Comtex SmarTrend(R) - Wed Jul 13, 12:01PM CDT
Mylan (NASDAQ:MYL) traded in a range yesterday that spanned from a low of $45.43 to a high of $46.78. Yesterday, the shares gained 1.5%, which took the trading range above the 3-day high of $45.39 on volume of 2.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
MYL: 46.74 (-0.05)
Teva Raises Q2 Guidance; to Unveil 2016-2019 View
Zacks Equity Research - Zacks Investment Research - Wed Jul 13, 6:47AM CDT
Ahead of its acquisition of Allergan's Generics business, Teva Pharmaceutical (TEVA) raised its second-quarter 2016 guidance for earnings and revenues.
IPXL: 31.15 (-0.27), AGN: 254.86 (+1.91), MYL: 46.74 (-0.05), TEVA: 53.61 (+0.11)
Mylan Launches Generic Temodar® Capsules
PR Newswire - Mon Jul 11, 6:30AM CDT
Mylan N.V. (NASDAQ, TASE: MYL) today announced the U.S. launch of Temozolomide Capsules, 5 mg, 20 mg, 100 mg, 140 mg, 180 mg and 250 mg, which is a generic version of Merck's Temodar®. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product. Temozolomide Capsules are indicated for the treatment of adult patients with newly diagnosed cancerous tumors known as glioblastoma multiforme concomitantly with radiotherapy and then as maintenance treatment.
MRK: 58.66 (unch), MYL: 46.74 (-0.05)
Mylan to Report Second Quarter 2016 Financial Results on August 9, 2016
PR Newswire - Thu Jul 07, 9:47AM CDT
Mylan N.V. (NASDAQ, TASE: MYL) today announced that it will host a conference call and live webcast, on Tuesday, August 9, 2016, at 4:30 p.m. EDT, to review the company's financial results for the second quarter ended June 30, 2016. Mylan will release its financial results on August 9, after the close of the U.S. financial markets.
MYL: 46.74 (-0.05)
Mylan Launches Generic Fenoglide® Tablets
PR Newswire - Wed Jul 06, 6:30AM CDT
Mylan N.V. (NASDAQ, TASE: MYL) today announced the U.S. launch of Fenofibrate Tablets USP, 40 mg and 120 mg, which is a generic version of Santarus's Fenoglide®. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated as adjunctive therapy to diet to reduce elevated low-density lipoprotein cholesterol, total cholesterol, Triglycerides, and apolipoprotein B to increase high-density lipoprotein in adult patients with primary hypercholesterolemia or mixed dyslipidemia.
MYL: 46.74 (-0.05)
Mylan Launches Generic Avodart® Capsules
PR Newswire - Fri Jun 24, 10:44AM CDT
Mylan N.V. (NASDAQ, TASE: MYL) today announced the U.S. launch of Dutasteride Capsules, 0.5 mg, the generic version of GlaxoSmithKline's Avodart® Capsules. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated as monotherapy for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate to improve symptoms, reduce the risk of acute urinary retention and reduce the risk of the need for BPH-related surgery. It may also be used with tamsulosin for the treatment of symptomatic BPH in men with an enlarged prostate.
MYL: 46.74 (-0.05), GSK: 45.25 (+0.18)
Mylan Donates EUR 1 Million to the Princess Máxima Center for Pediatric Oncology
PR Newswire - Thu Jun 23, 10:22AM CDT
Mylan N.V. (NASDAQ, TASE: MYL), one of the world's leading pharmaceutical companies, today announced a EUR 1 million donation to the Princess Máxima Center for Pediatric Oncology, a new national cancer center currently being built in Utrecht, the Netherlands.
MYL: 46.74 (-0.05)
Mylan Launches Generic Dexedrine® Capsules
PR Newswire - Mon Aug 01, 6:30AM CDT
Mylan N.V. (NASDAQ, TASE: MYL) today announced the U.S. launch of Dextroamphetamine Sulfate Extended-release Capsules, 5 mg, 10 mg, and 15 mg, a generic version of Amedra Pharmaceuticals LLC's Dexedrine®. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated in narcolepsy and attention deficit disorder with hyperactivity as an integral part of a total treatment program that typically includes other measures (psychological, educational, social) for patients (ages 6 years to 16 years) with this syndrome.(1)
MYL: 46.74 (-0.05)
Mylan Launches Generic Propecia® Tablets
PR Newswire - Mon Aug 01, 6:00AM CDT
Mylan N.V. (NASDAQ, TASE: MYL) today announced the U.S. launch of Finasteride Tablets USP, 1 mg, a generic version of Merck's Propecia®. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated for the treatment of male pattern hair loss (androgenetic alopecia) in men only.
MRK: 58.66 (unch), MYL: 46.74 (-0.05)
Mylan Falls 1.36% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Thu Jul 28, 1:42PM CDT
Mylan (NASDAQ:MYL) traded in a range yesterday that spanned from a low of $45.82 to a high of $46.92. Yesterday, the shares fell 1.4%, which took the trading range below the 3-day low of $46.38 on volume of 1.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
MYL: 46.74 (-0.05)
Look for Shares of Mylan to Potentially Rebound after Yesterday's 1.36% Sell Off
Comtex SmarTrend(R) - Thu Jul 28, 1:41PM CDT
Mylan (NASDAQ:MYL) traded in a range yesterday that spanned from a low of $45.82 to a high of $46.92. Yesterday, the shares fell 1.4%, which took the trading range below the 3-day low of $46.38 on volume of 1.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
MYL: 46.74 (-0.05)
Zacks.com featured highlights: Korea Electric Power, Third Point Reinsurance, Mylan N.V. and Gray Television
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 8:30AM CDT
Zacks.com featured highlights: Korea Electric Power, Third Point Reinsurance, Mylan N.V. and Gray Television
KEP: 27.37 (+0.18), MYL: 46.74 (-0.05), TPRE: 12.60 (+0.01), GTN: 9.78 (-0.12)
Mylan Receives U.S. FTC Clearance for Proposed Meda Acquisition
PR Newswire Europe - Wed Jul 27, 4:19PM CDT
Mylan Has Now Received All Antitrust Regulatory Clearances to Acquire Meda
MYL: 46.74 (-0.05)
4 Buy-Rated Stocks with High Earnings Yield
Zacks Equity Research - Zacks Investment Research - Wed Jul 27, 8:21AM CDT
Earnings yield is a useful ratio for investors who have exposure to both stocks and bonds.
KEP: 27.37 (+0.18), TPRE: 12.60 (+0.01), MYL: 46.74 (-0.05), GTN: 9.78 (-0.12)
The Zacks Analyst Blog Highlights: Manulife Financial, Mylan, Huntsman, Air Lease and Bofi Holding
Zacks Equity Research - Zacks Investment Research - Mon Jul 18, 8:30AM CDT
The Zacks Analyst Blog Highlights: Manulife Financial, Mylan, Huntsman, Air Lease and Bofi Holding
BOFI: 16.09 (-0.73), MFC: 13.42 (-0.21), AL: 28.58 (-0.23), MYL: 46.74 (-0.05), HUN: 15.41 (-0.05)
6 Stocks Still Trading Cheap in Today's Market
Zacks Equity Research - Zacks Investment Research - Fri Jul 15, 2:58PM CDT
We believe it's time to let go of popular stocks and instead focus on the ones trading below fair value.
BOFI: 16.09 (-0.73), MFC: 13.42 (-0.21), AL: 28.58 (-0.23), MYL: 46.74 (-0.05), HUN: 15.41 (-0.05), IX: 69.93 (-0.24)
Market Updates on Drugs - Generic Equities -- Mylan, Horizon Pharma, Allergan, and Diplomat Pharmacy
PR Newswire - Fri Jul 15, 6:30AM CDT
On Thursday, July 14, 2016, the NASDAQ Composite ended the trading session at 5,034.06, up 0.57%; the Dow Jones Industrial Average edged 0.73% higher, to finish at 18,506.41; and the S&P 500 closed at 2,163.75, up 0.53%. The gains were broad based as eight out of nine sectors ended the session in positive. Stock-Callers.com has initiated coverage on the following equities: Mylan N.V. (NASDAQ: MYL), Horizon Pharma PLC (NASDAQ: HZNP), Allergan PLC (NYSE: AGN), and Diplomat Pharmacy Inc. (NYSE: DPLO). Learn more about these stocks by accessing their free notes at:
AGN: 254.86 (+1.91), DPLO: 35.72 (-0.21), HZNP: 18.89 (-0.40), MYL: 46.74 (-0.05)
Teva (TEVA) Provides 2016-2019 Outlook, Shares Gain
Arpita Dutt - Zacks Investment Research - Thu Jul 14, 7:10AM CDT
Teva (TEVA) provided its preliminary outlook for 2016-2019 and expects the Actavis Generics acquisition to go through anytime soon.
AGN: 254.86 (+1.91), MYL: 46.74 (-0.05), TEVA: 53.61 (+0.11), RDY: 44.50 (+0.85)
Looking For Generic Drug Stocks? Pick Up These Winners
Zacks Premium Research - Zacks Investment Research - Wed Jul 13, 5:27PM CDT
The short term earnings outlook for these stocks have been building momentum recently, so don't miss out!
MYL: 46.74 (-0.05), RDY: 44.50 (+0.85), AMPH: 16.29 (+0.11)
SmarTrend Watching for Potential Pullback in Shares of Mylan After 1.51% Gain
Comtex SmarTrend(R) - Wed Jul 13, 12:01PM CDT
Mylan (NASDAQ:MYL) traded in a range yesterday that spanned from a low of $45.43 to a high of $46.78. Yesterday, the shares gained 1.5%, which took the trading range above the 3-day high of $45.39 on volume of 2.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
MYL: 46.74 (-0.05)
Teva Raises Q2 Guidance; to Unveil 2016-2019 View
Zacks Equity Research - Zacks Investment Research - Wed Jul 13, 6:47AM CDT
Ahead of its acquisition of Allergan's Generics business, Teva Pharmaceutical (TEVA) raised its second-quarter 2016 guidance for earnings and revenues.
IPXL: 31.15 (-0.27), AGN: 254.86 (+1.91), MYL: 46.74 (-0.05), TEVA: 53.61 (+0.11)
Mylan Launches Generic Temodar® Capsules
PR Newswire - Mon Jul 11, 6:30AM CDT
Mylan N.V. (NASDAQ, TASE: MYL) today announced the U.S. launch of Temozolomide Capsules, 5 mg, 20 mg, 100 mg, 140 mg, 180 mg and 250 mg, which is a generic version of Merck's Temodar®. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product. Temozolomide Capsules are indicated for the treatment of adult patients with newly diagnosed cancerous tumors known as glioblastoma multiforme concomitantly with radiotherapy and then as maintenance treatment.
MRK: 58.66 (unch), MYL: 46.74 (-0.05)
Mylan to Report Second Quarter 2016 Financial Results on August 9, 2016
PR Newswire - Thu Jul 07, 9:47AM CDT
Mylan N.V. (NASDAQ, TASE: MYL) today announced that it will host a conference call and live webcast, on Tuesday, August 9, 2016, at 4:30 p.m. EDT, to review the company's financial results for the second quarter ended June 30, 2016. Mylan will release its financial results on August 9, after the close of the U.S. financial markets.
MYL: 46.74 (-0.05)
Mylan Launches Generic Fenoglide® Tablets
PR Newswire - Wed Jul 06, 6:30AM CDT
Mylan N.V. (NASDAQ, TASE: MYL) today announced the U.S. launch of Fenofibrate Tablets USP, 40 mg and 120 mg, which is a generic version of Santarus's Fenoglide®. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated as adjunctive therapy to diet to reduce elevated low-density lipoprotein cholesterol, total cholesterol, Triglycerides, and apolipoprotein B to increase high-density lipoprotein in adult patients with primary hypercholesterolemia or mixed dyslipidemia.
MYL: 46.74 (-0.05)
Mylan Launches Generic Avodart® Capsules
PR Newswire - Fri Jun 24, 10:44AM CDT
Mylan N.V. (NASDAQ, TASE: MYL) today announced the U.S. launch of Dutasteride Capsules, 0.5 mg, the generic version of GlaxoSmithKline's Avodart® Capsules. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated as monotherapy for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate to improve symptoms, reduce the risk of acute urinary retention and reduce the risk of the need for BPH-related surgery. It may also be used with tamsulosin for the treatment of symptomatic BPH in men with an enlarged prostate.
MYL: 46.74 (-0.05), GSK: 45.25 (+0.18)
Mylan Donates EUR 1 Million to the Princess Máxima Center for Pediatric Oncology
PR Newswire - Thu Jun 23, 10:22AM CDT
Mylan N.V. (NASDAQ, TASE: MYL), one of the world's leading pharmaceutical companies, today announced a EUR 1 million donation to the Princess Máxima Center for Pediatric Oncology, a new national cancer center currently being built in Utrecht, the Netherlands.
MYL: 46.74 (-0.05)
